Trial SWOG-S1211

A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab (NSC-764479) for Newly Diagnosed High-Risk Multiple Myeloma (HRMM).

Type: Cancer Therapy
Phase: Phase I/II
Status: Open to Accrual
Treatments: Anti-Angiogenesis, Chemotherapy: Systemic, Immunomodulator, Immunotherapy
Randomized: Yes
Defintions of terms and FAQ about clinical trials.

Trial Leaders/Researchers: Sikander Ailawadhi, M.D.
Other Trial Staff: Christine Duran, D.M., Teh-Chun Wang, R.N.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov

For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.